TCTR20170711001招募中4 期
Doxorubicin, Cyclophosphamide followed by Paclitaxel vs. 5-FU,Doxorubicin, Cyclophosphamide in locally advanced BreastCancer
适应症
试验速览
- 阶段
- 4 期
- 状态
- 招募中
- 入组人数
- 154
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 Years 至 70 Years（—）
- 性别
- Female
入选标准
- •Patients willing to be included in this study.
- •ï‚· Histopathologically proven invasive ductal carcinoma.
- •ï‚· No prior chemotherapy, radiotherapy or breast surgery.
- •ï‚· Patients are required to have Eastern Co-operative Oncology Group (ECOG) performance
- •status up to scale 2.
- •ï‚· Female sex.
- •ï‚· Patients without distant metastasis.
排除标准
- •Pregnant or lactating woman.
- •ï‚· Patients dropped out or lost to follow up before completion of study.
- •ï‚· Serious concomitant medical illness including severe heart disease, uncontrolled diabetes
- •mellitus, or hypertension.
- •ï‚· Life expectancy < 6 months.
- •ï‚· Male sex.
- •ï‚· Initial surgery (excluding diagnostic biopsy) of the primary site.
- •ï‚· Patients with distant metastasis.
- •ï‚· Patients with double primaries.
研究者
相似试验
已完成
不适用
A Double-Blind Phase III Trial of Doxorubicin and Cyclophosphamide Followed by Paclitaxel With Bevacizumab or Placebo in Patients With Lymph Node Positive and High Risk Lymph Node Negative Breast Cancer-C50 Malignant neoplasm of breastMalignant neoplasm of breastC50PER-015-09EASTERN COOPERATIVE ONCOLOGY GROUP (ECOG),
终止
2 期
Chemotherapy & Bevacizumab for Human Epidermal Growth Factor Receptor 2 (HER2)/Neu-Negative Stage II/III Breast CancerHER2-negative Breast CancerStage II Breast CancerStage IIIA Breast CancerStage IIIB Breast CancerStage IIIC Breast CancerNCT00679029University of Nebraska15
进行中（未招募）
1 期
A phase II study of doxorubicin, cyclophosphamide and vindesine with valproic acid in patients with refractory or relapsing small cell lung cancer after platinum derivatives and etoposide.This is a prospective phase II study investigating well-known chemotherapeutic (doxorubicin, cyclophosphamide, vindesine) and antiepileptic (valproate) agents, in combination, for the treatment of refractory or recurrent small cell lung carcinoma after platinum derivatives and etoposide, for which no standard treatment is available in this indication.EUCTR2008-004278-41-BEInstitut Jules Bordet43
进行中（未招募）
不适用
Cyclophosphamide, Doxorubicin, Vincristine, Prednisone plus Rituximab (CHOP-R) and Cyclophosphamide, Pixantrone, Vincristine, Prednisone plus Rituximab (CPOP-R) in Elderly Patients with Diffuse Large-B-cell Lymphoma: A Phase II, Randomized, Multicenter, Comparative Trial'Diffuse Large-Bcell LymphomaMedDRA version: 14.1Level: PTClassification code 10012818Term: Diffuse large B-cell lymphomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2005-001100-40-ITCELL THERAPEUTICS INC. SEDE SECONDARIA280
进行中（未招募）
不适用
Cyclophosphamide, Doxorubicin, Vincristine, Prednisone plus Rituximab (CHOP-R) andCyclophosphamide, Pixantrone, Vincristine, Prednisone plus Rituximab (CPOP-R) inPatients with Diffuse Large-B-cell Lymphoma: A Phase II, Randomized,Multicenter, Comparative TrialDiffuse large B-cell lymphoma.MedDRA version: 13.1Level: PTClassification code 10012818Term: Diffuse large B-cell lymphomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2005-001100-40-DECell Therapeutics Europe S.r.l.280